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The primary purpose of this study was to document the incidence 
of clinical and subclinical spontaneous abortion in women who have no 
reproductive capability impairment. The relationship between prior 
oral contraceptive use and a subsequent increased incidence of 
spontaneous subclinical abortion was investigated. 
Background 
The incidence of clinically apparent spontaneous abortion ranges 
1 2 
from 8.3 percent to 15 percent. ' Since factors such as increasing 
maternal age, prior spontaneous abortion, and possibly increasing 
gravidity increase the relative risk of abortion, there is no "normal" 
2 
incidence of abortion that applies to all women. Abortion risk in-
creases with advancing maternal age, particularly after age 35 and 
3_g 
especially over age 40. A history of prior spontaneous abortion • , u 4,6,8,9 increases the risk of subsequent spontaneous abortion, 
especially if the first abortion was associated with a normal 
8 10 
karyotype. ' The effects of increasing gravidity are controversial; 
some investigators claim this factor constitutes an increasing risk 
for spontaneous abortion;^'^ others dispute the relevance of 
. , 12,13 gravidity. 
Sources of Bias in Studies 
Factors affecting empirically determined rates of spontaneous 
abortions have been described in the literature under two major 
2 
2 categories: observational factors and artifactual factors. Obser-
vational factors relate to the confirmation of a spontaneous abortion. 
For instance a subclinical abortion may be missed due to delayed 
pregnancy confirmation and/or lack of clinical symptoms, or alterna-
tively falsely confirmed due to sporadically delayed menses from 
isolated anovulatory cycles or ovulatory cycles with prolonged folli-
cular phases. Additionally, induced abortions may be falsely reported 
as spontaneous abortions, artificially elevating the reported inci-
dence of spontaneous abortions. 
Artifactual factors include memory artifact, compensation artifact, 
recurrence artifact, and selection artifact. Memory artifact is 
particularly significant in retrospective studies, where the longer 
the interval between the abortion and the time of questioning the more 
likely it may be forgotten. A compensation artifact refers to the 
voluntary decision to either persist or desist from further pregnancy 
attempts according to the outcome of previous pregnancies. For 
instance, the experience of a prior spontaneous abortion may cause the 
woman to become discouraged and desist from further pregnancy attempts. 
A recurrence artifact is purely statistical and its influence on 
study design is variable, depending on the length of the study period. 
Since the probability for the occurrence of a spontaneous abortion is 
more likely the longer the study period, and the risk for a subsequent 
abortion higher once one or more prior abortions have occurred, the 
longer the study period the higher the reported incidence of spontaneous 
abortion will be. 
A selection artifact refers to the period in time when observa-
tion is started. Retrospective studies requiring a pregnancy of 
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certain gestational age for entry are biased by the age selected. 
Prospective studies which follow a confirmed pregnancy are biased by 
the exclusion of early abortions which may or may not be apparent to 
the women but escape medical evaluation. The selection artifact is 
absent if recruitment is confined to nonpregnant women. 
Retrospective studies have reported higher incidences of spon-
taneous abortions, while prospective studies have reported lower in-
cidences. Both types of studies are subject to the various biases 
previously discussed and include only those abortions which are 
clinically apparent. Abortion incidences from retrospective studies 
are considered to be most accurate with ranges of 13-15 percent 
reported. ^ P r o s p e c t i v e studies which recruit women already pregnant 
have reported incidences of spontaneous abortions less than ten per-
cent due to the exclusion of early clinical abortions not medically 
evaluated and therefore not included.^'^ The most ideal study re-
cruits nonpregnant women and observes subsequent pregnancies and 
losses.^ 
Subclinical Abortion 
The notion of subclinical abortion is derived from the confirma-
tion of elevated human chorionic gonadotropin- (HCG) in women with 
missed periods who subsequently menstruate with either normal or 
moderately increased flow."^ "4 Although the existence of subclinical 
abortion is confirmed by such studies, it does not give any indication 
of the frequency with which it occurs. In an attempt to estimate the 
frequency of both clinical and subclinical spontaneous abortion, 
Chartier and co-investigators prospectively screened a group of 
4 
infertile women who demonstrated objective evidence of ovulation. 
Conception was confirmed by the presence of HCG in the serum. The 
16 incidence of total abortion derived from this group was 37 percent. 
Pregnancy loss projections based on the number of abnormal versus 
normal fertilized ova recovered from hysterectomy specimens give an 
incidence of spontaneous abortion of 29 percent."*"^  There are no 
studies which indicate to what extent these results are applicable to 
normal populations. Applying a correction factor to empirically 
determined incidences of spontaneous abortions to account for subclinical 
abortions increases the overall abortion rate in the normal population 
2 
to about 20 percent. Speculative mathematical calculations suggest 
18 
that about 78 percent of all conceptions are eventually aborted. 
It is estimated that about one-third of all early pregnancy losses are 
18 
due to chromosomal abnormalities. 
The Normal Menstrual Cycle 
A normal menstrual cycle can be described in three separate 
phases: the follicular, the ovulatory, and the luteal phase. The 
follicular phase lasts 8-21 days, resulting in follicular maturation 
and ovulation. Major hormonal influences during this stage include 
Follicle Stimulating Hormone (FSH) and estradiol, with low estradiol 
levels at the beginning of the cycle stimulating FSH release and high 
estradiol levels at the end of the cycle inhibiting FSH release. At 
sufficiently high levels of estradiol, Lutenizing Hormone (LH) re-
lease is stimulated resulting in the midcycle LH surge and ovulation 
on about day 14. 
Within about 24 hours of the LH surge, rupture of the follicle 
and release of the ovum takes place. This marks the beginning of the 
luteal phase with LH and estradiol levels dropping rapidly following 
ovulation. Primary hormones supporting the luteal phase are progester-
one and estradiol. Gonadotropin concentrations remain low. Beginning 
10-12 days after ovulation the corpus luteum enters a stage of regres-
sion with normal time from LH surge to menses being approximately 
14 days. Should pregnancy take place, survival of the corpus luteum 
is prolonged by emergence of HCG. HCG first appears at 9-13 days after 
ovulation. 
Gonadotropins FSH and LH are secreted by the anterior pituitary 
in response to hypothalamic release of gonadotropin releasing factor. 
The ovarian hormones, estrogen and progesterone, stimulate the endo-
metrium to secretory and deciduous phases, respectively. 
Oral Contraceptive Effects 
Combination oral contraceptive agents prevent ovulation by inhi-
bition of gonadotropin secretion at either the hypothalamic or pituitary 
19 
level. Through a negative feedback mechanism the progestational 
agent suppresses LH secretion and the estrogenic agent suppresses FSH 
and LH secretion. Secondary mechanisms of contraceptive action in-
clude a hostile endometrial environment not receptive to implantation 
of the fertilized ovum and a thickened cervical mucus impervious to 
sperm transport. Progestogen effects predominate when both estrogen 
and progestogen are given together. 
Suppression of both basal and reserve gonadotropic (FSH and LH) 
release occurs in women maintained on oral contraceptive agents after 
9 
as few as three months of low dose oral contraceptives. Suppression 
of endogenous ovarian estrogen production has also been reported to 
occur after three months of low dose oral contraceptives. Recovery of 
gonadotropin and estradiol concentrations to pretreatment levels occurs 
9 20 
within the first cycle after discontinuation of oral contraceptives. ' 
Return to normal hypothalamic-pituitary-ovarian axis function is rapid 
following oral contraceptive use. 
Although 87-97 percent of women will resume normal ovulation with-
in three cycles following the use of oral contraceptive agents, a delay 
21 
in the return of spontaneous ovulation has been reported. Ovulation 
usually occurs between three to four weeks following discontinuation 
20 
of oral contraceptives. The delay in return to the normal midcycle 
rise of LH has been attributed to a prolongation of the follicular 
phase in the first post-oral contraceptive cycle. Since normal pre-
menses follicular stimulation does not occur in oral contraceptive 
users until after the agent is discontinued, the subsequent follicular 
phase is prolonged. 
Monthly conception rates following oral contraceptive agents, as 
compared to prior users of other contraceptive methods, are con-
22 
siderably lower. Conception rates are particularly low for the 
first three post-pill months and the delay in conception may be 13 
22 
months or greater for 25 percent of prior oral contraceptive users. 
Former oral contraceptive use has been reported to decrease fertility 
23 
rates for up to 42 months after discontinuing the agents. The 
overall conception pattern during the 12 months after oral contra-
ceptives are discontinued shows distinct peaks in the conception rate 
24 
at intervals of about four months. The reasons for such a pattern 
are purely speculative and a subclinical pregnancy loss followed by a 
period of infertility is one possible explanation which fits the 
7 
pattern. Fertility impairment is independent of the length of time on 
23 
oral contraceptive agents. The incidence of clinically evident 
spontaneous abortion following oral contraceptive use is not signifi-
25-27 
cantly increased. Prior users of intrauterine devices have also 
been reported to have lower monthly fertility rates than prior users 
22 
of other contraceptive methods other than oral contraceptives. This 
effect is seen primarily in the first three post-contraceptive-
months . ^  
In summary, despite the rapid recovery of hypothalamic-pituitary-
ovarian function and the rapid return to normal ovulatory cycles after 
oral contraceptives, there is a marked delay in the return to normal 
fertility rates which is unexplained. Although the occurrence of 
spontaneous clinical abortion in women conceiving after cessation of 
oral contraceptive agents is approximately the same as that compared 
to other methods of contraception, the possibility exists that early 
subclinical pregnancy loss could be occurring with increased frequency 
in post-oral contraceptive users. Knowledge of empirically determined 
clinical and subclinical pregnancy loss is limited to abnormal popula-
tions. Estimates of clinical and subclinical pregnancy loss in normal 
populations are limited to correction factors applied to clinically 
apparent abortion rates in normal populations and mathematical manipu-
lations based on average coital frequency and the probability of 
fertilization with each act of unprotected coitus. The primary purpose 
of this study was to document the incidence of clinical and subclinical 




Women between the ages of 19 to 33 who actively desired pregnancy 
were enrolled in the study for a period of time up to five ovulatory 
cycles. The total study group included 18 women. Women in the study 
group reported varied prior contraceptive use, including spermicides 
(1), barrier methods (8), combination barrier/spermicidal methods 
(2), intrauterine devices (IUD) (3), and oral contraceptives (4). The 
group included two women with a prior history of spontaneous abortion, 
two women with a prior history of induced abortion, six women with a 
prior history of successful delivery, and eight women with no history 
of either pregnancy or abortion. 
Inclusion and Exclusion Criteria 
Women with a history of infertility problems or menstrual ir-
regularities and those taking agents known to stimulate ovulation or 
prolactin were excluded. Women with a possible baseline pregnancy 
test at the time of the study entry were also excluded. Informed con-
sent was obtained from each woman prior to enrollment in the study and 
a photocopy of the consent form was placed in the chart and the second 
copy given to the participant. The study was reviewed and approved by 
the Institutional Review Board of the University of Utah. All women 
were required to be actively desiring pregnancy and to have discon-
tinued all methods of contraception at the time of study entry. A 
basal body temperature chart was kept by all women during the period 
of observation. Women were required to be at least 18 years of age. 
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Ovulation and Pregnancy Determinations 
Evidence of ovulation was objectively confirmed by either a sus-
tained midcycle rise in temperature or luteal phase serum progesterone 
concentrations >_ 5 ng/mL. Progesterone determinations were made during 
week three and week four of each cycle. Pregnancy was confirmed by 
serum concentrations of HCG >_ 5 mlU/mL. Whole blood specimens were 
collected in sterile tubes, then centrifuged and the serum drawn off. 
Serum was stored at -20° Celsius until analysis. Serum HCG determina-
tions were made during the initial week of enrollment and during week 
four of each cycle. If a delay in menses occurred, repeat HCG deter-
minations were made the following week. If a pregnancy was confirmed, 
repeat HCG determinations were made weekly for two weeks; thereafter, 
HCG was measured biweekly for up to eight weeks post-conception. 
Serum HCG was analyzed by an immunoradiometric assay (RIA) 
manufactured by Hybritech. There is no reported cross-reactivity be-
tween the assay method used and either gonadotropins or other hormones. 
The assay utilizes a two-site binding technique with the HCG molecule 
which eliminates cross-reactivity with molecular fragments of HCG. 
Only certain malignancies such as choriocarcinoma, hydatidiform mole, 
and some nontrophoblastic malignancies, including testicular tumors, 
prostatic cancer, breast cancer and lung cancer other than pregnancy 
28 
are known to cause elevations in serum HCG.- The assay is sensitive 
to 5 mlU/mL HCG, has an interassay variation of 4.7-10.7 percent and an 
intraassay variation of 3.6-7.5 percent (manufacturer's data). 
Serum progesterone was analyzed using an immunoradiometric (RIA) 
assay manufactured by Nuclear Medical Systems, Inc. The assay method 
10 
has a sensitivity to 25 pg/mL progesterone and an interassay variation 
of 8.1-13.0 percent and an intraassay variation or 6.1-9.0 percent 
(manufacturer's data). 
Analysis 
The difference in the incidence of pregnancies and spontaneous 
abortions between prior oral contraceptive users and prior users of 
other contraceptive methods was compared statistically using the 
Fishers Exact Test. 
RESULTS 
A total of 40 cycles were followed in the study period; eight 
cycles in prior users of oral contraceptives and 32 cycles in prior 
users of other contraceptive methods. Former oral contraceptive users 
had been continuous users prior to entry into the study for two months 
to two and one-half years. Oral contraceptives were discontinued 
from one week to one and one-half months prior to the study. Women 
who had used contraceptives other than oral contraceptive agents had 
not used oral contraceptives within three months of study entry. Prior 
users of contraceptive methods other than oral contraceptives had dis-
continued the agents from one day to five months prior to entry into 
the study. 
Table 1 lists spontaneous abortions, maintained pregnancies, and 
total pregnancies in prior oral contraceptive users and prior users of 
other contraceptive methods. The incidence of spontaneous early preg-
nancy loss in non-oral contraceptive users was 50 percent, and the 
incidence of spontaneous early pregnancy loss in prior oral contracep-
tive users was 33 percent. The overall incidence of spontaneous preg-
nancy loss in the total group was 46 percent. 
11 
Spontaneous abortions stratified according to cycle are listed in 
Table 2. These data show that pregnancy losses were equally distributed 
over the first three cycles of the study. Table 3 lists the cycle in 
which the maintained pregnancies occurred. Maintained pregnancies 
occurred during Cycle I, Cycle II, and Cycle IV. 
Three of the spontaneous pregnancy losses were asymptomatic while 
three were symptomatic. In the symptomatic group, one loss occurred 
within three weeks of conception, the second within six weeks of con-
ception, and the third loss occurred more than nine weeks after con-
ception. Symptoms consisted of pain, heavier or longer than usual 
menstrual flow, or the passage of tissue. All three asymptomatic 
losses occurred within three weeks of conception. Thus, the later a 
spontaneous abortion occurred post-conception, the more likely it was 
to be accompanied by the presence of symptomatology. 
Prior contraceptive methods employed by members of the study 
group are listed in Table 4. Barrier methods included the diaphragm, 
the condom, and the cervical cap. The IUD used by the study subjects 
® 
was the Copper-7 . Spermicidal agents included both contraceptive foam 
and vaginal suppositories. The greatest number of spontaneous abor-
tions per cycle occurred in the combined spermicides/barrier method 
group (20 percent); the second greatest number per cycle occurred in 
the barrier group (17 percent). Both the IUD and the oral contracep-
tive group had an occurrence of 12.5 percent spontaneous abortions per 
cycle. None occurred in the spermicides group. 
Table 5 lists the ages of the women in the group in relation to 
pregnancy outcome (status). All spontaneous abortions occurred in the 
12 
group aged >_ 25; none occurred in the group aged _< 24. Most maintained 
pregnancies (71 percent) occurred in the group aged j< 24. 
Two women originally enrolled in the study group showed no 
evidence of ovulation either by serum progesterone concentrations or 
basal body temperature charts. These women were not considered in the 
data analysis. All other women showed evidence of ovulatory cycles. 
No spontaneous losses or pregnancies occurred in either of the two 
women showing no evidence of ovulation. No pattern could be detected 
from basal body temperature charts which would be predictive of eventu-
al pregnancy loss. 
Tables 6 and 7 show the results of the statistical analysis be-
tween prior oral contraceptive users and prior users of other methods 
in terms of spontaneous abortions and total pregnancies. There was no 
statistically significant difference between the two groups in the 
frequency of either spontaneous abortions or total pregnancies 
(p > 0.05). 
DISCUSSION 
The design of this study attempted to avoid as many of the factors 
• % 
which introduce bias as possible. Observational factors were minimized 
by the use of the most sensitive method of pregnancy confirmation 
available. It is possible that some spontaneous pregnancy losses were 
missed due to the limited sensitivity of the assay method or an early 
fourth week serum analysis. In an attempt to minimize this limitation, 
all samples were run in duplicate and any samples that measured between 
5-10 MIU/mL HCG or were < 5 MIU/mL and associated with clinical symptoms 
of a spontaneous abortion were reassayed. All pregnancy tests were per-
formed as late in the cycle as possible, in order to allow the maximum 
amount of time between conception and pregnancy testing. It is doubt-
ful that any spontaneous abortions in this group were actually purpose-
fully induced since all women desired pregnancy. Selection artifact is 
absent since recruitment was limited to nonpregnant women as confirmed 
by baseline pregnancy testing. Memory artifact is not a factor in 
this study since objective evidence of pregnancy is relied on for 
documenting fertility. Although all study participants claimed to be 
actively desiring pregnancy throughout the study period, it is possible 
that some participants may have been unconsciously modifying pregnancy 
attempts after they were told of a spontaneous abortion. If there is 
a compensation type artifact present in this study, it would have to 
be an unconscious rather than a conscious act. The recurrence arti-
fact was minimized in this study by the short period of observation. 
The maximum amount of time that any individual was observed was five 
cycles. Although the rate of spontaneous abortion was high in this 
group, no woman experienced more than one spontaneous abortion during 
the period of observation. 
The incidence of spontaneous abortion (46 percent) observed in 
this study is higher than empirically determined rates of spontaneous 
4 11 
abortion in normal populations (13-15 percent). ' The 13-15 percent 
figures refer only to clinically evident spontaneous abortions while 
the data from this study includes both clinical and subclinical 
spontaneous abortions. In addition, all prior studies suffer from 
the types of biases previously discussed. Primary biases in this study 
design would include observational factors and possibly compensation 
factors. Observational factors would tend to decrease the incidence 
of spontaneous abortions determined in this study, although to a 
14 
lesser degree than the effect on previous studies. If compensation 
factors do exist in this study, their effects are impossible to pre-
dict since all women in the study claimed to be actively desiring preg-
nancy throughout the period of observation. 
Data from series of women with abnormal fertility patterns indi-
cate an incidence of 29-37 percent spontaneous abortions which in-
cludes both clinical and subclinical losses.^'^ Mathematical pro-
jections based on probabilities estimate that 78 percent of all concep-
18 
tions are eventually aborted. The incidence of 46 percent derived 
from this study is greater than incidences derived from studies of 
women with abnormal fertility rates and less than rates derived from 
mathematical projections. Spontaneous abortion rates in this study may 
be higher than rates derived from abnormal populations since women with 
abnormal fertility patterns may actually conceive less often than 
women with normal fertility patterns. Every attempt possible was 
made in this study to exclude women with a history of either documented 
or suspected abnormality in fertility in order to study as normal a 
population as possible. The incidence of spontaneous abortion ob-
served in this study may be a more accurate reflection of the actual 
incidence in normal populations since it includes both clinical and 
subclinical abortion. Three spontaneous abortions in this study group 
were clinically apparent and subsequently medically evaluated. The 
incidence of clinically apparent spontaneous abortion in this group 
was 23 percent. 
The incidence of spontaneous abortion in prior oral contraceptive 
users (33 percent) is lower than that of prior users of other contra-
ceptive methods (50 percent). The initial data suggest that oral 
15 
contraceptive agents do not increase the incidence of spontaneous sub-
clinical abortion although the study group is too small to form any 
firm conclusions. The contraceptive group with the greatest number 
of spontaneous abortions per cycle was the combination barrier/ 
spermicide group (20 percent). The second largest group was in the 
barrier contraceptive group (17 percent). The ages of the eight women 
in the barrier contraceptive group ranged from 22-23 with most (75 
percent) 25 years or older. The high incidence of spontaneous loss 
in this group may be related to the high proportion of older women in 
this group. The number of women in other groups was too small to per-
mit any valid conclusion on the incidence of spontaneous pregnancy 
loss. No contraceptive method has been identified as a risk factor 
22 
for subsequent pregnancy loss except possibly the IUD. 
Risk factors for spontaneous abortion include increasing maternal 
age, prior spontaneous abortion, and possibly increasing gravi-
3-8 9-13 
dity. ' Since only two women in the study group reported a 
history of prior spontaneous abortion, the group was too small to 
permit any observations on the influence of prior spontaneous abortion 
on subsequent pregnancy loss. Since increasing gravidity has not been 
clearly identified as a risk factor for spontaneous abortion, no 
attempt was made to look for an association in this study. Stratifi-
cation of the study group according to age revealed that 100 percent 
of the spontaneous abortions occurred in the group aged _> 25. The 
small size of the various age groups in the study group probably would 
not permit an age-related trend to become apparent. Abortion risk has 
3—8 
been reported to particularly increase after age 35. Since the 
oldest woman in the study group was age 33, it was not possible to 
confirm this observation in the present study group. Although not as 
striking, a reciprocal relationship was seen in relation to pregnancy 
maintenance since 71 percent of the maintained pregnancies occurred in 
the group aged j< 24. 
CONCLUSION 
The incidence of spontaneous abortion in this study was 46 percent. 
No statistically significant difference in the number of pregnancies or 
spontaneous abortions between different prior methods of contraception 
was found. Since the number of women discontinuing oral contraceptives 
was so small, no firm conclusions can be made regarding any dif-
ferences at this time. An increased incidence of spontaneous abortion 
occurred in the group aged >_ 25 years in this study. 
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Table 1. Overall Study Results 
Parameter 
Prior Users of Contra-
ceptives Other Than 
Oral Contraceptives 
Prior Oral 





















Table 2. Spontaneous Abortions Per Cycle 
Percentage of 
Spontaneous 
Number Spontaneous Abortion per 
of Women Abortions Total Women 
Cycle I 18 3 17 
Cycle II 12 2 17 
Cycle III 6 1 17 
Cycle IV 3 0 0 
Cycle V 1 0 0 
TOTAL .... . . . 40 6 
20 
Table 3. Maintained Pregnancies Per Cycle 
Percentage of 
Spontaneous 
Number Maintained Abortion per 
Cycle of Women Pregnancies Total Women 
Cycle I 18 4 22 
Cycle II 12 2 17 
Cycle III 6 0 0 
Cycle IV 3 1 33 
Cycle V 1 0 0 
TOTAL 40 
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Table 4. Contraceptives Used Prior to Study Entry in Relation to 
Spontaneous Abortions and Maintained Pregnancies 
Percentage of 
Number Number Cycles with 
of of Spontaneous Maintained Spontaneous 



















TOTAL 18 40 
Table 5. Age Range of Study Group in Relation to Spontaneous 
Abortions and Maintained Pregnancies 
Age Spontaneous Maintained 
(years) Number Abortions Pregnancies Total 
19-21 2 0 2 2 
22-24 5 0 3 3 
25-27 5 3 1 4 
28-30 2 1 1 2 
31-33 4 2 0 2 
TOTAL ... 18 6 7 13 
Table 6. Statistical Analysis of Total Pregnancies per Cycle 
Prior Users of Contra-
ceptives Other Than 
Oral Contraceptives Oral Contraceptives Total 
Number of Cycles 
with Pregnancies 3 10 13 
Number of Cycles 
without Pregnancies 5 22 27 
TOTAL 8 32 40 
p > 0.05 
24 
Table 7. Statistical Analysis of Spontaneous Abortions per Cycle 
Prior Users of 
Contraceptives 
Prior Users of Other Than 
Oral Contraceptives Oral Contraceptives Total 
Number of Cycles with 
Pregnancy Losses 1 5 6 
Number of Cycles with-
out Pregnancy Losses 7 27 34 
TOTAL 8 32 40 
p > 0.05 
APPENDIXES 
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THE INCIDENCE OF SPONTANEOUS PREGNANCY LOSS IN WOMEN 
DISCONTINUING ORAL CONTRACEPTIVE AGENTS 
Consent Form 
Background Information 
You are invited to participate as one of 40 women in this research 
study evaluating the number of miscarriages following the use of 
birth control pills as compared to other contraceptive methods. 
During the first few months after stopping birth control pills, women 
experience difficulty in getting pregnant. The purpose of this study 
is to investigate the possibility that early pregnancy loss not de-
tectable by either the woman (e.g., by presence of a heavier than 
usual menstrual flow) or her physician (e.g., by physical exam) may be 
a factor involved in difficulty getting pregnant. The availability of 
a new blood test which measures human chorionic gonadotropin (HCG) is 
able to detect pregnancies before the first missed period. This test 
differs from the usual pregnancy tests which use a urine sample to 
detect pregnancy usually two weeks after the first missed period. 
Research Study Design 
Women who enroll in the study will be required to discontinue all 
methods of birth control in order to become pregnant. A baseline preg-
nancy test will be performed at the time of enrollment. For women discon-
tinuing oral contraceptives weekly blood progesterone (for evidence of 
ovulation) and HCG concentrations will be checked until onset of the first 
menstrual period. Thereafter, weekly blood tests will be checked 
starting with week 3 of the menstrual cycle and continuing until onset 
of menstruation; the cycle repeating itself each month. Women dis-
continuing other methods of contraception will be enrolled during the 
first week of the menstrual cycle and weekly blood tests performed in 
the same manner starting with week 3 of the menstrual cycle and con-
tinuing until onset of menstruation. If pregnancy should be confirmed, 
HCG concentrations will be continued weekly for the first month, there-
after only as the clinical situation dictates. All women will be asked to 
maintain daily basal body temperature charts during the entire period 
of study enrollment. Women will be enrolled in the study for a period 
of time not exceeding six months. All blood tests will be collected by 
routine means with 5 mL or 1 teaspoonful of blood taken for each test. 
Risks 
The risks involved in the study are: local pain and a very slight risk 
of infection at the site of the blood draw. 
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Benefits 
I understand that all pregnancy and ovulation tests done in connection 
with this study will be available to me at no cost. Basal body tempera-
ture thermometers and charts will be given to me at no cost. In 
addition, I will receive free pregnancy testing and $50.00 after com-
pleting the study. 
Additional Study Guidelines 
In agreeing to participate, I understand that the study is voluntary 
and that if I choose to withdraw from the study, I will continue to re-
ceive the same care as others not choosing to participate. I also 
understand that I can quit the study at any time I desire. If I have 
any additional questions regarding this research, I can call Dr. 
Maurice Emery (581-3044) or Ms. Martha Joy (581-5941) or Dr. Michael 
Caudle (581-7647). 
I realize that my records will be maintained with strict confidential-
ity by study investigators. My records will not be made available to 
anyone outside the confines of the study or clinic unless special 
permission is granted by me. 
Medical Treatment of Compensation for Physical Injury: In the event 
you sustain physical injury resulting from the research project in 
which you are participating, the University of Utah will provide you, 
without charge, emergency and temporary medical treatment not other-
wise covered by insurance. Furthermore, if your injuries are caused 
by negligent acts or omissions of University employees acting in the 
course and scope of their employment, the University may be liable, 
subject to limitations prescribed by law, for additional medical costs 
of other damages you sustain. If you believe that you have suffered 
a physical injury as a result of participation in this research pro-
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